ARCHIVES

PV-10 Produces 51 Percent Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Carbone Names NCI Clinical Director, Rauscher shuffles Treatment Activities

August 30, 1974

In Brief: Hisserich Named USC Assistant VP, Replaced By Rideout At Cancer Center; DeVita Assures Groups

June 27, 1986

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

July 25, 2014

Denman Hammond, NCCF Founder, Receives Award.

November 17, 2000

Approval Granted For New Formulation of Lupron Depot

July 29, 2011

ODAC Votes For Approval Of PegIntron For Melanoma, Votrient For Renal Cancer

October 9, 2009